Supportive Regulatory Frameworks Fostering Adoption of
Recombinant Cell Culture Supplements in Biopharmaceutical
Applications
ROCKVILLE, Md., June 20, 2024 /PRNewswire/ -- According to a
newly published research report by Fact.MR, the global
Recombinant Cell Culture Supplement Market is set to be
valued at US$ 2.87 billion in
2024 and is projected to expand at 7.3% CAGR from 2024 to
2034. By the end of 2034, the market is anticipated to grow to
US$ 5.81 billion in size.
Recombinant cell culture supplements are becoming more popular,
which is a direct outcome of increased financing for research and
development in the life sciences and pharmaceutical industries. The
fact that it is feasible to consistently offer consistent, secure,
and efficient conditions for cell culture procedures explains the
popularity of these supplements. As businesses and academic
institutions focus on creating advanced biopharmaceuticals,
vaccines, and treatments, reliable and superior cell culture
conditions are becoming more crucial and further driving the
recombinant cell culture supplement market growth.
Recombinant supplements help address this demand by boosting
cell viability, proliferation, and output through the use of exact
and reliable formulations. As a result, scientific developments and
biomanufacturing techniques advance in effectiveness and
productivity.
For More Insights into the Market, Request a Sample of this
Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10218
Key Takeaways from the Market Study:
- The East Asia market is
forecasted to expand at a CAGR of 6.7% from 2024 to 2034.
- North America is projected to
account for 29.9% of the global market share in 2024.
- Sales of recombinant cell culture supplements in the United States are forecasted to reach
US$ 1.28 billion by 2034.
- The microorganism segment is estimated to reach a market value
of US$ 2.9 billion in 2024.
- By product, sales of recombinant growth factors are projected
to reach US$ 4.25 billion by the end
of 2034.
- Based on end users, revenue from biopharmaceutical companies is
calculated to reach US$ 1.92 billion
by the end of 2034.
"Switching to a serum-free culture medium is leading to
the development of recombinant cell culture supplements that
provide essential nutrients and growth hormones to ensure the
survival and functionality of cells," says a Fact.MR
analyst
Growing Demand for Microorganism-based Recombinant Cell
Culture Supplements
Recombinant cell culture supplements generated from
microorganisms are in great demand because of their important
role in various biotechnological and medical applications. These
supplements are used in bioreactors and cell culture systems to
provide essential nutrients, growth factors, and other biomolecules
that support the establishment, maintenance, and differentiation of
various cell lines.
As the biopharmaceutical and biotechnology industries expand, so
does the need for reliable, consistent, and high-quality
recombinant cell culture supplements derived from microorganisms to
support several research, development, and production
activities.
Get Customization on this Report for Specific Research
Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=10218
More Valuable Insights on Offer:
Fact.MR, in its new offering, presents an unbiased analysis of
the recombinant cell culture supplement market, presenting
historical demand data (2019 to 2023) and forecast statistics for
2024 to 2034.
The study divulges essential insights into the market based on
product (recombinant growth factors, recombinant insulin,
recombinant albumin, recombinant transferrin, recombinant trypsin,
recombinant aprotinin, recombinant lysozyme), application (stem
cell therapy, gene therapy, bioprocess application, vaccine
development), source (animals, microorganisms, humans), and
end-user (academic & research institutes, biopharmaceutical
companies, cancer research centers, contract research
organizations), across seven major regions of the world
(North America, Western Europe, Eastern Europe, East
Asia, Latin America,
South Asia & Pacific, and
MEA).
Recent Developments:
Key players in the recombinant cell culture supplement industry
are differentiating themselves from rivals and meeting a wide range
of customer needs by using strategies including product diversity.
Businesses are focusing on providing end-user-focused solutions by
creating exclusive formulas, proprietary technologies, and
customized services.
- STEMCELL Technologies, Inc. launched a new line of recombinant
growth factors for cell culture in December
2022.
- In October 2022, Abcam plc
launched a new line of recombinant cytokines for cell culture.
- Sino Biological Inc. launched a new line of animal-free cell
culture media in September 2022.
Related Market Projections for 2034:
Blood Pressure Management Supplement Market is predicted
to reach a valuation of $43.7 billion
by 2033.
Glucose Management Supplement Market is expected to reach
$17.5 billion by 2034, rising at a
CAGR of 6.1%.
Detox Support Supplement Market is expanding from an
estimated $993.5 million in 2024 to a
colossal $1.84 billion by 2034,
fueled by a CAGR of 6.3%.
3D Cell Culture Market is forecasted to reach
$1.42 billion, advancing at a CAGR of
9.5% by 2034.
Gene Therapy Market is expanding at a CAGR of 14.1% and
is forecasted to reach $38.52 billion
by 2034.
Cell Culture Media Market is forecasted to reach
$6.94 billion by 2034, at a CAGR of
7.1% from 2024 to 2034.
Vitamin Supplement Market is projected to reach
$115.5 billion by 2034, expanding at
a CAGR of 7.5%
CRISPR and Cas Genes Market is expected to grow at a
remarkable 20% CAGR through 2033.
About Us:
Fact.MR is a distinguished market research company
renowned for its comprehensive market reports and invaluable
business insights. As a prominent player in business intelligence,
we deliver deep analysis, uncovering market trends, growth paths,
and competitive landscapes. Renowned for its commitment to accuracy
and reliability, we empower businesses with crucial data and
strategic recommendations, facilitating informed decision-making
and enhancing market positioning.
With its unwavering dedication to providing reliable market
intelligence, FACT.MR continues to assist companies in navigating
dynamic market challenges with confidence and achieving long-term
success. With a global presence and a team of experienced analysts,
FACT.MR ensures its clients receive actionable insights to
capitalize on emerging opportunities and stay ahead in the
competitive landscape.
Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
View original
content:https://www.prnewswire.co.uk/news-releases/recombinant-cell-culture-supplement-market-to-surpass-5-81-billion-by-2034-with-a-7-3-cagr--factmr-302177123.html